AGA SectionAmerican Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome
Abbreviations used in this paper
AGA
American Gastroenterological Association
CI
confidence interval
CSBM
complete spontaneous bowel movement
FDA
Food and Drug Administration
GRADE
Grading of Recommendations Assessment, Development and Evaluation
IBS
irritable bowel syndrome
IBS-C
irritable bowel syndrome with constipation
IBS-D
irritable bowel syndrome with diarrhea
IBS-M
irritable bowel syndrome with mixed pattern
PEG
polyethylene glycol
PICO
population, intervention, comparator, and outcome(s)
QOL
quality of life
RCT
randomized controlled trial
RR
relative risk
SBM
spontaneous bowel movement
SSRI
selective serotonin reuptake inhibitor
TCA
tricyclic antidepressant
Cited by (0)
Conflicts of interest The authors disclose the following: Lin Chang is a consultant/advisory board member for Ironwood, Forest, Entera Health, QOL Medical, and receives research support from Ironwood Pharmaceuticals. Anthony Lembo is a consultant/advisory board member for Ironwood, Forest, Salix, and Prometheus.
Reprint requests Address requests for reprints to: Chair, Clinical Practice and Quality Management Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: [email protected]; telephone: (301) 941-2618.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.